Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights
November 08, 2022 08:00 ET
|
Nuvectis Pharma, Inc.
The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansion portion is expected to begin in Q1 2023 Investigational New Drug...
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
October 03, 2022 16:30 ET
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma Announces Formation of a Scientific Advisory Board
September 28, 2022 08:00 ET
|
Nuvectis Pharma, Inc.
FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment...
Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma
September 13, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences
September 07, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement
August 01, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
July 27, 2022 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
Nuvectis Pharma Announces FDA Clearance of IND for NXP800
June 21, 2022 08:15 ET
|
Nuvectis Pharma, Inc.
FORT LEE, NJ,, June 21, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
May 20, 2022 10:21 ET
|
Nuvectis Pharma, Inc.
FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
April 13, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...